Score a VH/VL sequence for developability liabilities and anti-drug-antibody risk in one report — in seconds, before you commit bench time. Free to try, no account or sales call.
Most candidates fail on developability or immunogenicity — often after months at the bench. PresciaBio surfaces those liabilities from sequence, on day zero.
Paste a VH or VL domain and the engine flags chemical-liability and manufacturability hotspots as you watch — the same logic behind the API. It runs in your browser; nothing is uploaded.
Demo flags primary-sequence motifs. Production scoring is CDR-weighted & structure-aware.
We number every sequence in IMGT, Kabat & Chothia and weight liabilities by region and exposure. A flag in framework is noise; the same flag in an exposed CDR is a red line.
numbering schemes, auto-aligned
Sub-2-second scoring, batch-ready for thousands of clones.
MHC-II epitope mapping & anti-drug-antibody scoring on your leads.
Flag thresholds informed by published clinical-stage antibody profiles (Raybould 2019), reported as green / amber / red.
One REST call drops scoring straight into your discovery stack.
Deamidation (NG/NS), isomerization (DG/DS), Met & Trp oxidation, N-glycosylation sequons, unpaired cysteines, and DP fragmentation — surfaced and ranked, with the residue positions called out.
The in-browser demo runs sequence-level liability checks today. CDR-weighting, structure-based metrics, and the immunogenicity module are the production engine, in active development.
Run it on every clone, every round.
The step that protects a whole program.
One report per candidate: a developability and ADA-risk read, the flagged positions, and where it sits against clinical-stage molecules. An illustrative example:
| Position | Region | Finding | Risk |
|---|---|---|---|
| N55–G56 | CDR-H2 | Asn deamidation (NG) | High |
| D101–G102 | CDR-H3 | Asp isomerization (DG) | High |
| 9-mer @ 52 | CDR-H2 | T-cell epitope · DRB1*04:01 | Elevated |
| M34 | CDR-H1 | Met oxidation | Moderate |
Recommendation: engineer out the CDR-H2 NG and CDR-H3 DG motifs; ADA risk is driven by a single CDR-H2 epitope — a candidate for deimmunization. The live demo computes the developability portion in your browser.
Liabilities and epitopes aren't abstract — they sit on the antibody's structure. This is a real intact IgG (PDB 1IGT): heavy chains in cyan, light chains in pink. Drag to rotate.
Reference structure shown. In a report, your candidate's own model (ABodyBuilder2) is rendered with its flagged residues highlighted.
An ADA prediction is only worth acting on if it tracks what the wet lab and the clinic see. The immunogenicity engine is built on the same biology those assays measure, and is meant to be checked against them.
MHC class II binding and CD4⁺ T-cell epitope content across a panel of common HLA-DR alleles, using established binding predictors.
The peptides MAPPs (MHC-associated peptide proteomics) recovers, and the responses DC–T-cell and T-cell proliferation assays measure — the usual experimental readouts for T-cell-driven immunogenicity.
Scores are referenced to published clinical anti-drug-antibody rates for approved antibodies, so a low score reads as “in the range of well-tolerated molecules.”
Scope: ADA is multifactorial — aggregation, impurities, dose and route all contribute. This addresses the sequence- and T-cell-epitope component. The methods and benchmarks are from the peer-reviewed literature, not proprietary validation we have not yet run; paired in-silico / wet-lab results will be posted here as we generate them.
No. The scanner runs entirely in your browser — sequences you paste are analyzed locally and are not uploaded to or stored on our servers. If you later use the API or a paid engagement, anything you send is covered by the agreement and treated as confidential.
Sequence-level liability motifs — deamidation (NG/NS), isomerization (DG/DS), Met/Trp oxidation, N-glycosylation sequons, unpaired cysteines, DP fragmentation — plus estimated pI and net charge. CDR-weighting, structure-based metrics, and the immunogenicity module are the production engine, available through pilots and the paid tiers.
MHC class II binding and CD4⁺ T-cell epitope screening across a panel of common HLA-DR alleles, mapped to what wet-lab assays measure (MAPPs, DC–T-cell). It addresses the sequence- and T-cell-driven component of anti-drug-antibody risk; aggregation, impurities, and dose are separate contributors.
No. It is for triage and prioritization — it supports, but does not replace, experimental characterization or regulatory assessment.
Fixed scope, fixed fee, about one to two weeks. We start with a mutual NDA; you send a small candidate panel; you get a report per candidate — flags with positions, a ranked shortlist, and recommended edits — plus a readout call.
The scanner is free to use. Paid tiers are published and in early access; pilots are fixed-fee. See Pricing.
Free academic tools each do one thing. Enterprise suites do everything, behind a sales process. PresciaBio is the focused middle: developability and ADA risk in one self-serve report, priced in the open.
| Capability | Free point tools | Enterprise suites | PresciaBio |
|---|---|---|---|
| Developability flags | ✓ | ✓ | ✓ |
| Immunogenicity / ADA risk | — | ✓ | Early access |
| Both in one report | — | Sometimes | ✓ |
| Instant, self-serve | ✓ | — | ✓ |
| Published pricing | Free | — | ✓ |
| REST API | — | ✓ | ✓ |
| Runs in your browser, no upload | — | — | ✓ |
A generalized comparison of tool categories, not specific vendors. “Early access” = in active development.
No gating to find out what it costs. Start on the free tier; paid tiers add full biophysics, batch, and the immunogenicity module.
Prices shown are launch drafts for review. The scanner is free to use now; paid tiers are in early access — request access and we'll set you up.
We start with a mutual NDA. You send a small set of VH/VL candidates — no integration, no setup.
Developability liabilities and anti-drug-antibody risk, interpreted by an antibody engineer — not just raw scores.
A report per candidate with the positions to fix, a ranked shortlist, and a 30-minute call to walk through it.
Numbering & developability as a clean REST endpoint — the same engine behind the live demo. Free to start, usage-billed at scale.
Get an API key# POST a sequence, get a verdict curl https://api.presciabio.com/v1/developability \ -H "Authorization: Bearer $KEY" \ -d '{"vh":"EVQLVESGGG…","scheme":"imgt"}' # → { "score":82, "verdict":"low-risk", "flags":[{"motif":"NG","pos":55, "region":"CDR-H2","risk":"high"}] }